Quality by Design (QbD) driven Systematic Development of Nano-lipoidal Carrier of Poorly Water Soluble Anti-tubercular agent-Rifabutin.

ABSTRACT

In the present research work, Rifabutin, drug used for tuberculosis infection, was encapsulated in lipidic nanoparticles with a view to develop a sustained release oral formulation. The nanocarrier loaded rifabutin, prepared by the solvent diffusion evaporation method and evaluated for its physical (nanoparticles size distribution) and chemical (drug content) stability. To optimize the identified independent variables, Box-Behnken Design (BBD) was utilized effectively. The result showed that a size of optimized formulation was found to be 315 ± 10.96 nm and PDI of 0.310 ± 0.05; the encapsulation efficiency was found to be (66.3 ± 3.85). On encapsulation, the nanocarrier showed amorphous pattern of drug studied using X-ray Diffractometric analysis. The release pattern of rifabutin loaded nanocarrier revealed that it represents the sustained release kinetics in comparison to plain drug. Thus, nanotechnology-based formulation may reduce frequency, provide medications more efficaciously, ultimately reducing patient avoidance.

KEYWORDS:

• Nanocarrier
• mycobacterium tuberculosis
• rifabutin
• qbd
• box-Behnken Design

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This Research work did not receive any type of funding from any funding agencies in the public, commercial, or not-for-profit sectors.